Skip to main content
TARA
NASDAQ Life Sciences

Baker Brothers Affiliate Files Intent to Sell $220K in Protara Therapeutics Shares Amid Coordinated Disposition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$6.15
Mkt Cap
$320.111M
52W Low
$2.77
52W High
$7.82
52W Position info
122% above low
Off High info
21% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

TARA has more than doubled off its 52-week low of $2.77.

Summary

667, L.P., an affiliate of Baker Brothers Life Sciences, has filed a Form 144 indicating its intent to sell 35,173 shares of Protara Therapeutics common stock, valued at approximately $220,151. This is part of a larger, coordinated disposition by the institutional investor group.


Key Events · Ownership and Investor Activity · TARA

  • Intent to Sell Shares

    667, L.P., an affiliate of Baker Brothers Life Sciences, intends to sell 35,173 shares of Protara Therapeutics common stock.

  • Significant Transaction Value

    The proposed sale is valued at approximately $220,151.

  • Part of Coordinated Disposition

    This sale is explicitly linked to a larger, coordinated disposition by the Baker Brothers group, totaling 459,298 shares across related filings.

  • Institutional Investor Selling

    The filer is a "Former Affiliate" of Baker Brothers Life Sciences, indicating a reduction in their investment.


Analysis · TARA · Life Sciences

This Form 144 filing from 667, L.P., an affiliate of Baker Brothers Life Sciences, signals a continued reduction in their stake in Protara Therapeutics. While the proposed sale of 35,173 shares (valued at approximately $220,151) is modest on its own, the filing explicitly states it's part of a larger, coordinated disposition by the institutional group totaling 459,298 shares across related filings. This ongoing selling pressure from a significant former affiliate could create an overhang on the stock, especially following recent positive clinical trial results which might have provided a liquidity window for the investor. Investors should monitor further filings from this group for signs of a complete exit or continued selling pressure.

At the time of this filing, TARA was trading at $6.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $320.1M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TARA - Latest Insights

TARA
Jul 01, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $4.04
Real-time Price: $3.94 info
Change: -$0.100 (-2%) info
Market Cap: $225.941M info
TARA
Jun 29, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.16
Real-time Price: $3.94 info
Change: -$0.220 (-5%) info
Market Cap: $225.941M info
TARA
Jun 29, 2026, 4:52 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $3.94 info
Change: -$0.220 (-5%) info
Market Cap: $225.941M info
TARA
Jun 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.94
Real-time Price: $3.94 info
Change: $0 (0%) info
Market Cap: $225.941M info
TARA
May 28, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.74
Real-time Price: $3.94 info
Change: -$0.800 (-17%) info
Market Cap: $225.941M info